FDA: Type 2 diabetes medicine Jardiance may cause ketoacidosis

On May 15 2015, the Food and Drug Administration (FDA) issued a Drug Safety Communication warning Jardiance (empagliflozin) users about possible links between the type 2 diabetes medication and developing serious medical conditions. Jardiance may be linked to ketoacidosis, a serious medical condition which may require hospitalization. Individuals who suffered severe side effects may be eligible to file a Jardiance lawsuit in order to receive compensation for damages.

Jardiance is in a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors. The FDA approved SGLT2 inhibitors to treat diabetes along with changes in diet and exercise. The FDA’s May 2015 Drug Safety Communication also included the SGLT2 inhibitors Invokana (canagliflozin), Invokamet (canagliflozin and metformin), Farxiga (dapagliflozin), Xigduo XR (dapagliflozin and metformin extended-release), and Glyxambi (empagliflozin and linagliptin).

Possible links between taking SGLT2 inhibitors and developing serious health problems are being evaluated by the FDA, Health Canada, and the European Medicines Agency. SGLT2 inhibitors are being evaluated by independent health organizations for possible links to increased risk of heart attack and stroke.

What is Jardiance?

Jardiance is a once-daily pill taken to treat type 2 diabetes developed and marketed by Boehringer Ingelheim and Eli Lilly and Company. The FDA first approved Jardiance for use by adults with type 2 diabetes in August 2014.

Jardiance is and other SGLT2 inhibitors treat type 2 diabetes by making the kidneys expel excess sugar through urine. Jardiance is prescribed in 10mg and 25mg dosages. The active ingredient in Jardiance, empagliflozin, is also found in Glyxambi, which is also developed and marketed by Boehringer Ingelheim and Eli Lilly and Company.

Side effects of Jardiance

The FDA, Health Canada, and European Medicines Agency are all evaluating SGLT2 side effects. Serious side effects of SGLT2 inhibitors include:

Ketoacidosis

Heart attack

Stroke

Kidney failure

Death

SGLT2 inhibitors linked to ketoacidosis

Ketoacidosis is one of the most serious side effects of taking SGLT2 inhibitors. Ketoacidosis occurs when the body can not produce enough insulin to promote the proper absorption of blood acids called ketones. Excessive amounts of ketones will cause the blood’s pH level to drop and may lead to hospitalization for nausea, difficulty breathing, vomiting, shortness of breath, confusion and dehydration.

Jardiance SGLT2 inhibitor lawsuit

If you or a loved one suffered a serious injury while taking Jardiance or another SGLT2 inhibitor like Invokana, you may be entitled to substantial compensation. The experienced and dedicated product liability attorneys of The Cochran Firm, D.C. can help you recover lost wages, hospital bills, medical expenses, pain and suffering, and other damages.

The Cochran Firm, D.C. is offering Jardiance injury victims free, prompt, and confidential case reviews. Since we represent our clients on a contingency basis, there are absolutely no legal fees unless we win your case.

Call The Cochran Firm, D.C. during business hours at 202-682-5800 or at 1-800-THE-FIRM (843-3476) to reach us 24 hours a day. You may also fill out a contact form here on our website. Strict time deadlines apply when filing a Jardiance lawsuit so please contact The Cochran Firm, D.C. at your earliest convenience and preserve your rights.

About Us

The attorneys of The Cochran Firm, D.C. are providing free consultations for people who suffered health complications or side effects caused by Invokana and other type 2 diabetes medications.